NIPA like domain containing 4Genealiases: ARCI6 · ICHTHYIN · ICHYN · NIPA4 · SLC57A6
Q-omics provides the consensus-scored NIPAL4 profile across patient tissues and cancer cell-line models. NIPAL4 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NIPAL4 is differentially expressed in 11, with the highest sampling consensus in STAD. Additionally, NIPAL4 RNA expression shows 15,606 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, STAD, and HNSC as cancer lineages where NIPAL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIPAL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIPAL4 survival associations across molecular data types. NIPAL4 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIPAL4 RNA expression–survival associations across cancer types. High NIPAL4 expression shows unfavorable associations in KIRC, MESO, THCA, UVM and COAD, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NIPAL4 RNA expression.
This table summarizes NIPAL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NIPAL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIPAL4 shows lower tumor expression in STAD and higher tumor expression in HNSC, BRCA, LUSC, LUAD and KIRC. The STAD box plot shows higher NIPAL4 RNA expression in normal versus tumor tissue (log2 FC = −1.424, t-test p < 0.001).
This table shows molecular features associated with NIPAL4 in patient tissues and cancer cell lines. In patient samples, NIPAL4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, NIPAL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and URINARY_TRACT.
